BAIN Capital Investors LLC, 10% Owner at Kailera Therapeutics, Inc. (KLRA), bought 8,398,438 shares at $16.00 ($134.4M) on 2026-04-20, disclosed to the SEC on 2026-04-20.
Bain Capital Investors LLC purchased $134 million worth of KLRA shares at $16.00, marking the largest insider purchase in the company's history. This significant accumulation by a major shareholder comes shortly after the company completed its IPO and received positive analyst coverage regarding its obesity drug pipeline.
KLRA is currently trading 12.81% below its 52-week high of $28.23 and just 3.88% above its 52-week low of $23.69, indicating the stock is consolidating near recent lows following its April IPO.
Analyst coverage from William Blair on May 13, 2026, and other firms on May 12, 2026, provides a roadmap for the obesity drug pipeline; additionally, the company completed its IPO and governance overhaul on May 1, 2026.
The stock carries a short interest of 1.51% of the float, and the negative forward P/E of -5.62 indicates the company is currently unprofitable as it seeks to compete in the weight-loss market.
Negative factors outweigh the positive ones.
| Filing → |
| CERE | BUY | 2023-10-18 | $250.0M | — | Filing → |
| BFAM | SELL | 2017-11-16 | $611.7M | — | Filing → |
| VRTV | SELL | 2016-11-23 | $150.6M | — | Filing → |